Form 4: Caribou Biosciences' Chief Technology Officer Receives Stock Options and Restricted Stock Units

Timothy P. Kelly, Chief Technology Officer of Caribou Biosciences, acquired 37,500 restricted stock units and options to purchase 170,000 shares of common stock on February 20, 2025.

Summary

• On February 20, 2025, Timothy P. Kelly, the Chief Technology Officer of Caribou Biosciences, acquired 37,500 restricted stock units (RSUs) and options to purchase 170,000 shares of common stock.
• The RSUs vest in four equal annual installments starting February 20, 2026, contingent upon Kelly's continued service.
• These RSUs will be settled in stock within 30 days after each vesting date.
• 25% of the options will vest on February 20, 2026 (one-year anniversary of the grant date), with the remaining options vesting monthly over the subsequent 36 months, also subject to continued service.
• The exercise price for the options is $1.41.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management's interests with shareholders. The sentiment is neutral to slightly positive.

Positives

• The grant of RSUs and stock options to the CTO aligns his interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Caribou Biosciences' stock.
• If Kelly leaves the company before the vesting dates, he will forfeit the unvested RSUs and options.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Stock options and RSUs are common forms of compensation for executives in the biotechnology industry, aligning their interests with those of shareholders and incentivizing long-term growth.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in the biotech industry.
• Companies like CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics also utilize stock options and RSUs to incentivize their key personnel.
• The vesting schedules described are typical, with vesting occurring over a period of several years contingent on continued employment.

Stakeholder Impact

• Shareholders: The grant of equity to the CTO can be seen as a positive, aligning management's interests with shareholder value.
• Employees: The equity grants can boost employee morale by demonstrating the company's commitment to its leadership.

Key Dates

Keywords

Caribou Biosciences, CRBU, Timothy P. Kelly, stock options, restricted stock units, RSUs, Form 4, beneficial ownership, Chief Technology Officer, equity compensation